Hyphens Pharma International Ltd-Repositioning for growth

16 Nov 2020
  • 9M20 earnings of S$5.1mn were 17% below our estimate due to other losses arising from inventory obsolescence.
  • 3Q revenue grew 2% YoY to S$31.4mn as strength in proprietary brands offset specialty pharma and medical hypermart weakness.
  • COVID-19 led to S$565k in inventory obsolescence and S$217k FX losses.
  • Short-term weakness expected as company reorganises operations to manage thinning margins and heightened inventories.
  • Signed two distribution agreements in past month, to develop proprietary-brand business.
  • Maintain ACCUMULATE with reduced DCF TP (WACC 7.2%) of S$0.365 from S$0.495. We cut FY20e and FY21e earnings by 20% to reflect a recovery only in FY22.

The Positive

+ Proprietary brands sustained growth

Proprietary-brand revenue grew 23% YoY as the company continued to move sales online. Revenue was down 2% QoQ due to S$1mn of exceptional corporate sales of Ocean Health® supplements in the previous quarter. Stripping that out, QoQ growth would have been 26%, underscoring the strong organic growth of proprietary-brand products.

Specialty pharma and medical hypermart revenue was flat YoY though up 6%/4% QoQ. This reflected their recovery as Singapore gradually reopened.

The Negatives

– Inventory obsolescence hurt earnings

Inventory in excess of S$600k was marked down as a result of disruptions from COVID-19 across products:

  • Personal protective equipment like masks was marked down due to high supply resulting in lower selling prices and an influx of supply in the market, resulting in a net realisable value write-down of S$80k under cost of sales.
  • COVID-19 test kits that were procured in anticipation of high demand from widespread testing in Singapore had to be written off after the Singapore authorities centralised supply of test kits. However, the company is exploring options to re-sell the kits to other markets. About S$300k in value was written off with S$200k on the books remaining. This may be written off subsequently if no buyers are found.
  • S$100k of flu vaccines had to be written off due to lack of demand following travel restrictions. Flu vaccines have short shelf lives due to the different seasonal strains of flu viruses.
  • A further S$200k was written down for an assortment of products due to lockdowns in different markets which affected demand.

FX exposure

About S$217k in FX losses was recognised from SGD weakness against the USD/EUR as well as depreciation of the rupiah and peso.

Outlook

Repositioning business to capture long-term growth

The company continued to expand its proprietary-brand business with the signing of two distribution agreements: one for the distribution of Ocean Health® in Sri Lanka with Healthguard Pharmacy Limited (non-listed) and another for Ceradan® in China with Shanghai Good Luck International Trading Co. Ltd. (non-listed). We expect the company to continue investing in this business on account of better margins.

Normalisation expected in FY22

Inventories, receivables and payables may only normalise in FY22 after the company’s reorganisation of its operations.

Investment Action

Maintain ACCUMULATE with reduced DCF TP of S$0.365 from S$0.435

FY20e and FY21e earnings have been shaved by 20% to reflect a total write-off of COVID-19 test kits in the fourth quarter and a pushout in recovery to FY22e. We have also reduced margin expectations from their high base in FY19 and incorporated higher expenses from possible reinvestments in its own-brand business.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com